Featured Studies

Ebola vaccine inches toward human clinical trials

February 22, 2018

Written by: Terry Devitt

Ebola virus swarms the surface of a host cell in this electron micrograph. Like most viruses, Ebola requires the help of a host cell to survive and replicate. PHOTO: TAKESHI NODA, UNIVERSITY OF TOKYO – Photo credit: University of Wisconsin-Madison

A whole-virus vaccine to confront Ebola, the rare but often fatal hemorrhagic disease that periodically erupts in sub-Saharan Africa, may soon be one step closer to the clinic.

With the help of experts at Waisman Biomanufacturing, within the University of Wisconsin–Madison’s Waisman Center, UW–Madison School of Veterinary Medicine Professor Yoshihiro Kawaoka will lead a $3 million effort to produce as many as 1,000 doses of an experimental vaccine that has already been proven to work safely in monkeys.

It will be produced at Waisman Biomanufacturing, a specialized facility whose mission is to help translate scientific discovery into early-stage clinical trials. The staff of the facility provides expert help with manufacturing processes, quality control and overall product development in addition to regulatory support. Read more.

Published by University of Wisconsin-Madison February 21, 2018

‹ More Featured Studies